Full Breakdown
Hims & Hers Health Eyes Growth in Peptide Therapies Following FDA Announcement
4/17/2026, 11:58:17 AM
Regulatory Shift on Peptides
Hims & Hers Health, a telehealth company, is poised for potential growth in its peptide business following an announcement by Health and Human Services Secretary Robert F. Kennedy Jr. The U.S. Food and Drug Administration (FDA) plans to convene a Pharmacy Compounding Advisory Committee meeting to review the inclusion of certain peptides on the 503A bulk list. This designation would allow for the compounding of drugs on an individual prescribed basis rather than mass production, which could open new revenue streams for Hims & Hers as it shifts focus from its current GLP-1 offerings.
Background on Peptide Therapies
Peptides, which are short chains of amino acids, are being explored for various health applications, including metabolic health and anti-aging treatments. However, their long-term safety and effectiveness remain controversial due to limited scientific evidence and regulatory scrutiny. Hims & Hers has been preparing for this market by acquiring a California-based peptide manufacturing facility in February 2025, with CEO Andrew Dudum highlighting the potential of peptide innovation.
Market Implications
The FDA's review of peptides could significantly impact Hims & Hers' market position. Analysts from Leerink Partners view the FDA's decision as a positive development that could provide a clearer regulatory path for scaling peptide therapies. However, they caution that it may take time for these changes to translate into revenue. Currently, Hims & Hers shares have seen a notable increase, rising 6.88% in premarket trading after Kennedy's announcement, building on a previous 13.72% gain.
Criticism and Concerns
Despite the optimistic outlook, there are concerns regarding the implications of easing regulations on peptides. Former FDA official Dr. Peter Lurie warned that this shift could undermine the agency's drug vetting standards, suggesting that companies might opt for less rigorous compounding routes instead of pursuing full drug approvals. Additionally, some peptides, such as MK-677, are viewed as illegal when sold for human consumption, raising ethical and safety questions.
Official Statements & Responses
Hims Chief Medical Officer Dr. Patrick Carroll expressed support for the FDA's initiative, stating that it aims to bring peptide therapy into regulated, physician-led care. He emphasized the potential benefits of certain peptide therapies for public health. Conversely, Kennedy criticized the Biden administration for previously restricting peptide use, arguing that safety concerns were unfounded.
Conflicting Reports & Gaps
While the FDA's advisory meeting is scheduled for July, it is important to note that this process is still in its early stages, and immediate changes are not expected. Analysts have indicated that any financial benefits from the regulatory shift may not materialize until 2027, suggesting a cautious approach for investors.
What's Next
As the FDA prepares for its advisory meeting, the future of peptide therapies remains uncertain. Hims & Hers is expected to advocate for the inclusion of peptides on the compounding list, which could diversify its revenue streams beyond GLP-1 products. However, the company faces challenges, including declining net income and increasing competition from other market players like Amazon Pharmacy.